Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coloplast AS
Major medtech deals in November include Coloplast's $2.5bn acquisition of Atos Medical and Alcon's deal for Ivantis.
The deal is part of Coloplast’s Strive25 long-term financial strategy for revenue growth and sustainability.
The US FDA says final data from two Boston Scientific postmarket studies have reinforced the agency’s position that the company’s transvaginal mesh to treat pelvic organ prolapse (POP) has a poor benefit-risk profile. The firm’s mesh has been off the US market since 2019.
The settlement puts to rest product liability and patient safety suits in 47 states and the District of Columbia.
- Medical Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.